STAT3 and Familial prostate cancer: CAR, as a potential STAT3 blocker, has been reported to inhibit STATS phosphorylation, nuclear translocation, and DNA binding and to bind directly to the Src Homology 2 (SH2) domain of STAT3 and effectively inhibit its dimerization, significantly mitigating the growth and survival of prostate cancer cells and glioblastoma stem cells 16,22.